Epigenetic biomarkers in prostate cancer: Current and future uses

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 248-256

  Chiam, Karen ^a   Ricciardelli, Carmela ^b   Bianco Miotto, Tina ^b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Biomarkers; DNA methylation; Epigenetics; Histone modifications; MicroRNAs; Prostate cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; APC PROTEIN; GENOMIC DNA; GLUTATHIONE TRANSFERASE P1; HISTONE H3; HISTONE H4; MICRORNA; MICRORNA 141; MICRORNA 375; PROSTATE SPECIFIC ANTIGEN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DNA METHYLATION; EPIGENETICS; GLEASON SCORE; HISTONE MODIFICATION; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TREATMENT RESPONSE;

EID: 84888200099     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.011     Document Type: Review

References (151)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer J. Clin. 2011, 61:69-90.
2. Sakr W.A., Grignon D.J., Haas G.P., Heilbrun L.K., Pontes J.E., Crissman J.D. Age and racial distribution of prostatic intraepithelial neoplasia. Eur. Urol. 1996, 30:138-144.
3. Huggins C., Stephens R.C., Hodges C.V. Studies on prostatic cancer: the effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 1941, 43:209.
4. Scher H.I., Buchanan G., Gerald W., Butler L.M., Tilley W.D. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Rel. Cancer 2004, 11:459-476.
5. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Berenguer A., Maattanen L., Bangma C.H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B.G., Moss S.M., de Koning H.J., Auvinen A. Screening and prostate-cancer mortality in a randomized European study. New Engl. J. Med. 2009, 360:1320-1328.
6. Andriole G.L., Crawford E.D., Grubb R.L., Buys S.S., Chia D., Church T.R., Fouad M.N., Gelmann E.P., Kvale P.A., Reding D.J., Weissfeld J.L., Yokochi L.A., O'Brien B., Clapp J.D., Rathmell J.M., Riley T.L., Hayes R.B., Kramer B.S., Izmirlian G., Miller A.B., Pinsky P.F., Prorok P.C., Gohagan J.K., Berg C.D. Mortality results from a randomized prostate-cancer screening trial. New Engl. J. Med. 2009, 360:1310-1319.
7. Neal D.E., Donovan J.L. Prostate cancer: to screen or not to screen?. Lancet Oncol. 2000, 1:17-24.
8. Henrique R., Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur. Urol. 2004, 46:660-669. (discussion 669).
9. Roehrborn C.G., Boyle P., Gould A.L., Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999, 53:581-589.
10. Schatteman P.H., Hoekx L., Wyndaele J.J., Jeuris W., Van Marck E. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur. Urol. 2000, 37:404-412.
11. Djulbegovic M., Beyth R.J., Neuberger M.M., Stoffs T.L., Vieweg J., Djulbegovic B., Dahm P. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 2010, 341:c4543.
12. Shariat S.F., Semjonow A., Lilja H., Savage C., Vickers A.J., Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol. 2011, 50(Suppl 1):61-75.
13. Bjartell A., Montironi R., Berney D.M., Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol. 2011, 50(Suppl 1):76-84.
14. Roobol M.J., Haese A., Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol. 2011, 50(Suppl 1):85-89.
15. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 2005, 45:629-656.
16. Karpinets T.V., Foy B.D. Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations. Carcinogenesis 2005, 26:1323-1334.
17. Lund A.H., van Lohuizen M. Epigenetics and cancer. Genes. Dev. 2004, 18:2315-2335.
18. Leader J.E., Wang C., Fu M., Pestell R.G. Epigenetic regulation of nuclear steroid receptors. Biochem. Pharmacol. 2006, 72(11):1589-1596.
19. Nightingale K.P., O'Neill L.P., Turner B.M. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr. Opin. Genet. Dev. 2006, 16:125-136.
20. Lu Q., Qiu X., Hu N., Wen H., Su Y., Richardson B.C. Epigenetics, disease, and therapeutic interventions. Ageing Res. Rev. 2006, 5:449-467.
21. Garcia-Manero G., Gore S.D. Future directions for the use of hypomethylating agents. Semin. Hematol. 2005, 42:S50-59.
22. Schulz W.A., Hatina J. Epigenetics of prostate cancer: beyond DNA methylation. J. Cell Mol. Med. 2006, 10:100-125.
23. Hake S.B., Xiao A., Allis C.D. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer 2004, 90:761-769.
24. Li L.C., Carroll P.R., Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl. Cancer Inst. 2005, 97:103-115.
25. Perry A.S., Foley R., Woodson K., Lawler M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Rel. Cancer 2006, 13:357-377.
26. Oka M., Meacham A.M., Hamazaki T., Rodic N., Chang L.J., Terada N. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine. Oncogene 2005, 24:3091-3099.
27. Szyf M., Pakneshan P., Rabbani S.A. DNA demethylation and cancer: therapeutic implications. Cancer Lett. 2004, 211:133-143.
28. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
29. Salozhin S.V., Prokhorchuk E.B., Georgiev G.P. Methylation of DNA - one of the major epigenetic markers. Biochemistry (Mosc) 2005, 70:525-532.
30. Hark A.T., Schoenherr C.J., Katz D.J., Ingram R.S., Levorse J.M., Tilghman S.M. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000, 405:486-489.
31. Chan M.F., Liang G., Jones P.A. Relationship between transcription and DNA methylation. Curr. Top Microbiol. Immunol. 2000, 249:75-86.
32. Nakao M. Epigenetics: interaction of DNA methylation and chromatin. Gene 2001, 278:25-31.
33. Zhang Z., Karam J., Frenkel E., Sagalowsky A., Hsieh J.T. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol. Oncol. 2006, 24:152-160.
34. Nguyen C.T., Weisenberger D.J., Velicescu M., Gonzales F.A., Lin J.C., Liang G., Jones P.A. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62:6456-6461.
35. Ng H.H., Bird A. DNA methylation and chromatin modification. Curr. Opin. Genet. Dev. 1999, 9:158-163.
36. Mellor J. Dynamic nucleosomes and gene transcription. Trends Genet. 2006, 22:320-329.
37. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5:37-50.
38. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
39. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
40. Zamore P.D., Tuschl T., Sharp P.A., Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101:25-33.
41. Hudder A., Novak R.F. miRNAs: effectors of environmental influences on gene expression and disease. Toxicol. Sci. 2008, 103:228-240.
42. Matzke M.A., Birchler J.A. RNAi-mediated pathways in the nucleus. Nat. Rev. Genet. 2005, 6:24-35.
43. Sato F., Tsuchiya S., Meltzer S.J., Shimizu K. MicroRNAs and epigenetics. Febs J. 2011, 278:1598-1609.
44. Ng E.K., Tsang W.P., Ng S.S., Jin H.C., Yu J., Li J.J., Rocken C., Ebert M.P., Kwok T.T., Sung J.J. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 2009, 101:699-706.
45. Garzon R., Liu S., Fabbri M., Liu Z., Heaphy C.E., Callegari E., Schwind S., Pang J., Yu J., Muthusamy N., Havelange V., Volinia S., Blum W., Rush L.J., Perrotti D., Andreeff M., Bloomfield C.D., Byrd J.C., Chan K., Wu L.C., Croce C.M., Marcucci G. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009, 113:6411-6418.
46. Weber B., Stresemann C., Brueckner B., Lyko F. Methylation of human microRNA genes in normal and neoplastic cells. Cell Cycle 2007, 6:1001-1005.
47. Lujambio A., Esteller M. How epigenetics can explain human metastasis: a new role for microRNAs. Cell Cycle 2009, 8:377-382.
48. Dobosy J.R., Roberts J.L., Fu V.X., Jarrard D.F. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 2007, 177:822-831.
49. Jeronimo C., Bastian P.J., Bjartell A., Carbone G.M., Catto J.W., Clark S.J., Henrique R., Nelson W.G., Shariat S.F. Epigenetics in prostate cancer: biologic and clinical relevance. Eur. Urol. 2011, 60:753-766.
50. Chan T.A., Glockner S., Yi J.M., Chen W., Van Neste L., Cope L., Herman J.G., Velculescu V., Schuebel K.E., Ahuja N., Baylin S.B. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med. 2008, 5:e114.
51. Yegnasubramanian S., Haffner M.C., Zhang Y., Gurel B., Cornish T.C., Wu Z., Irizarry R.A., Morgan J., Hicks J., Deweese T.L., Isaacs W.B., Bova G.S., De Marzo A.M., Nelson W.G. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008, 68:8954-8967.
52. Brothman A.R., Swanson G., Maxwell T.M., Cui J., Murphy K.J., Herrick J., Speights V.O., Isaac J., Rohr L.R. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome?. Cancer Genet. Cytogenet. 2005, 156:31-36.
53. Santourlidis S., Florl A., Ackermann R., Wirtz H.C., Schulz W.A. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999, 39:166-174.
54. Schulz W.A., Elo J.P., Florl A.R., Pennanen S., Santourlidis S., Engers R., Buchardt M., Seifert H.H., Visakorpi T. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes. Chromosomes Cancer 2002, 35:58-65.
55. Cho N.Y., Kim B.H., Choi M., Yoo E.J., Moon K.C., Cho Y.M., Kim D., Kang G.H. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J. Pathol. 2007, 211:269-277.
56. Yang B., Sun H., Lin W., Hou W., Li H., Zhang L., Li F., Gu Y., Song Y., Li Q., Zhang F. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry. Urol. Oncol. 2011.
57. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000, 16:168-174.
58. Miyamoto K., Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J. Clin. Oncol. 2005, 35:293-301.
59. Park J.Y. Promoter hypermethylation in prostate cancer. Cancer Control. 2010, 17:245-255.
60. Phe V., Cussenot O., Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int. 2010, 105:1364-1370.
61. Wu T., Giovannucci E., Welge J., Mallick P., Tang W.Y., Ho S.M. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br. J. Cancer 2011, 105:65-73.
62. Nakayama M., Bennett C.J., Hicks J.L., Epstein J.I., Platz E.A., Nelson W.G., De Marzo A.M. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 2003, 163:923-933.
63. Lee W.H., Morton R.A., Epstein J.I., Brooks J.D., Campbell P.A., Bova G.S., Hsieh W.S., Isaacs W.B., Nelson W.G. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 1994, 91:11733-11737.
64. Jeronimo C., Henrique R., Hoque M.O., Mambo E., Ribeiro F.R., Varzim G., Oliveira J., Teixeira M.R., Lopes C., Sidransky D. A quantitative promoter methylation profile of prostate cancer. Clin. Cancer Res. 2004, 10:8472-8478.
65. Li L.C., Okino S.T., Dahiya R. DNA methylation in prostate cancer. Biochim. Biophys. Acta. 2004, 1704:87-102.
66. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Li L.C., Kawahara M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res. 2005, 11:6582-6588.
67. Meiers I., Shanks J.H., Bostwick D.G. Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review. Pathology 2007, 39(2007):299-304.
68. Febbo P.G. Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2009, 27:3088-3090.
69. Hopkins T.G., Burns P.A., Routledge M.N. DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. Urology 2007, 69:11-16.
70. Nakayama M., Gonzalgo M.L., Yegnasubramanian S., Lin X., De Marzo A.M., Nelson W.G. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J. Cell. Biochem. 2004, 91:540-552.
71. Bastian P.J., Ellinger J., Wellmann A., Wernert N., Heukamp L.C., Muller S.C., von Ruecker A. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11:4097-4106.
72. Roupret M., Hupertan V., Yates D.R., Catto J.W., Rehman I., Meuth M., Ricci S., Lacave R., Cancel-Tassin G., de la Taille A., Rozet F., Cathelineau X., Vallancien G., Hamdy F.C., Cussenot O. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin. Cancer Res. 2007, 13:1720-1725.
73. Baden J., Green G., Painter J., Curtin K., Markiewicz J., Jones J., Astacio T., Canning S., Quijano J., Guinto W., Leibovich B.C., Nelson J.B., Vargo J., Wang Y., Wuxiong C. Multicenter evaluation of an investigational prostate cancer methylation assay. J. Urol. 2009, 182:1186-1193.
74. Baden J., Adams S., Astacio T., Jones J., Markiewicz J., Painter J., Trust C., Wang Y., Green G. Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0ng/ml using an investigational prostate cancer methylation assay. J. Urol. 2011, 186:2101-2106.
75. Bastian P.J., Palapattu G.S., Lin X., Yegnasubramanian S., Mangold L.A., Trock B., Eisenberger M.A., Partin A.W., Nelson W.G. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 2005, 11:4037-4043.
76. Roupret M., Hupertan V., Catto J.W., Yates D.R., Rehman I., Proctor L.M., Phillips J., Meuth M., Cussenot O., Hamdy F.C. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int. J. Cancer J. Int. du Cancer 2008, 122:952-956.
77. Bastian P.J., Ellinger J., Heukamp L.C., Kahl P., Muller S.C., von Rucker A. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur. Urol. 2007, 51:665-674. (discussion 674).
78. Woodson K., O'Reilly K.J., Ward D.E., Walter J., Hanson J., Walk E.L., Tangrea J.A. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics: Off. J, DNA Methylation Soc. 2006, 1:183-186.
79. Ellinger J., Haan K., Heukamp L.C., Kahl P., Buttner R., Muller S.C., von Ruecker A., Bastian P.J. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate 2008, 68:42-49.
80. Ellinger J., Bastian P.J., Haan K.I., Heukamp L.C., Buettner R., Fimmers R., Mueller S.C., von Ruecker A. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int. J. Cancer 2008, 122:138-143.
81. Rosenbaum E., Hoque M.O., Cohen Y., Zahurak M., Eisenberger M.A., Epstein J.I., Partin A.W., Sidransky D. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2005, 11:8321-8325.
82. Chiam K., Centenera M.M., Butler L.M., Tilley W.D., Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS ONE 2011, 6:e25634.
83. Horvath L.G., Mahon K.L., Qu W., Devaney J., Chatfield M.D., Paul C., Wykes R., Boyer M.J., Stockler M.R., Marx G.M., Sutherland R.L.C., Clark S.J. A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 2011, 29(suppl):abstr 4603.
84. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Perez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
85. Wei Y., Xia W., Zhang Z., Liu J., Wang H., Adsay N.V., Albarracin C., Yu D., Abbruzzese J.L., Mills G.B., Bast R.C., Hortobagyi G.N., Hung M.C. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 2008, 47:701-706.
86. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
87. Barlesi F., Giaccone G., Gallegos-Ruiz M.I., Loundou A., Span S.W., Lefesvre P., Kruyt F.A., Rodriguez J.A. Global histone modifications predict prognosis of resected non small-cell lung cancer. J. Clin. Oncol. 2007, 25:4358-4364.
88. Van Den Broeck A., Brambilla E., Moro-Sibilot D., Lantuejoul S., Brambilla C., Eymin B., Khochbin S., Gazzeri S. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin. Cancer Res. 2008, 14:7237-7245.
89. Zhou L.X., Li T., Huang Y.R., Sha J.J., Sun P., Li D. Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy. Asian J. Androl. 2010, 12:171-179.
90. Park Y.S., Jin M.Y., Kim Y.J., Yook J.H., Kim B.S., Jang S.J. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Annu. Surg. Oncol. 2008, 15:1968-1976.
91. Ellinger J., Kahl P., von der Gathen J., Rogenhofer S., Heukamp L.C., Gutgemann I., Walter B., Hofstadter F., Buttner R., Muller S.C., Bastian P.J., von Ruecker A. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70:61-69.
92. Bianco-Miotto T., Chiam K., Buchanan G., Jindal S., Day T.K., Thomas M., Pickering M.A., O'Loughlin M.A., Ryan N.K., Raymond W.A., Horvath L.G., Kench J.G., Stricker P.D., Marshall V.R., Sutherland R.L., Henshall S.M., Gerald W.L., Scher H.I., Risbridger G.P., Clements J.A., Butler L.M., Tilley W.D., Horsfall D.J., Ricciardelli C. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol. Biomar. Prev. 2010, 19:2611-2622.
93. Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., Wang Q., Chia D., Goodglick L., Kurdistani S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174:1619-1628.
94. Wei Y., Xia W., Zhang Z., Liu J., Wang H., Adsay N.V., Albarracin C., Yu D., Abbruzzese J.L., Mills G.B., Bast R.C., Hortobagyi G.N., Hung M.C. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 2008, 47:701-706.
95. Rogenhofer S., Kahl P., Mertens C., Hauser S., Hartmann W., Buttner R., Muller S.C., von Ruecker A., Ellinger J. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int. 2012, 109:459-465.
96. Ellinger J., Kahl P., von der Gathen J., Heukamp L.C., Gutgemann I., Walter B., Hofstadter F., Bastian P.J., von Ruecker A., Muller S.C., Rogenhofer S. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest. 2011, 30:92-97.
97. Rhodes D.R., Sanda M.G., Otte A.P., Chinnaiyan A.M., Rubin M.A. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl. Cancer Inst. 2003, 95:661-668.
98. Hoffmann M.J., Engers R., Florl A.R., Otte A.P., Muller M., Schulz W.A. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol. Ther. 2007, 6:1403-1412.
99. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
100. van Leenders G.J., Dukers D., Hessels D., van den Kieboom S.W., Hulsbergen C.A., Witjes J.A., Otte A.P., Meijer C.J., Raaphorst F.M. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur. Urol. 2007, 52:455-463.
101. Laitinen S., Martikainen P.M., Tolonen T., Isola J., Tammela T.L., Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int. J. Cancer 2008, 122:595-602.
102. Yu J., Rhodes D.R., Tomlins S.A., Cao X., Chen G., Mehra R., Wang X., Ghosh D., Shah R.B., Varambally S., Pienta K.J., Chinnaiyan A.M. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007, 67:10657-10663.
103. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24:268-273.
104. Deligezer U., Akisik E.E., Erten N., Dalay N. Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clin. Chem. 2008, 54:1125-1131.
105. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11:426-437.
106. Deligezer U., Yaman F., Darendeliler E., Dizdar Y., Holdenrieder S., Kovancilar M., Dalay N. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin. Chim. Acta. 2010, 411:1452-1456.
107. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
108. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA. 2008, 105:10513-10518.
109. Pang Y., Young C.Y., Yuan H. MicroRNAs and prostate cancer. Acta Biochimica et Biophysica Sinica 2010, 42:363-369.
110. Coppola V., de Maria R., Bonci D. MicroRNAs and prostate cancer. Endocr. Rel. Cancer 2010, 17:1-17.
111. Saini S., Majid S., Dahiya R., Diet microRNAs and prostate cancer. Pharm Res 2010, 27:1014-1026.
112. Catto J.W., Alcaraz A., Bjartell A.S., De Vere White R., Evans C.P., Fussel S., Hamdy F.C., Kallioniemi O., Mengual L., Schlomm T., Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol. 2011, 59:671-681.
113. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., Miller K., Lein M., Kristiansen G., Jung K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126:1166-1176.
114. Martens-Uzunova E.S., Jalava S.E., Dits N.F., van Leenders G.J., Moller S., Trapman J., Bangma C.H., Litman T., Visakorpi T., Jenster G. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2011, 31:978-991.
115. Brase J.C., Johannes M., Schlomm T., Falth M., Haese A., Steuber T., Beissbarth T., Kuner R., Sultmann H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer. J. Int. du Cancer 2011, 128:608-616.
116. Wach S., Nolte E., Szczyrba J., Stohr R., Hartmann A., Orntoft T., Dyrskjot L., Eltze E., Wieland W., Keck B., Ekici A.B., Grasser F., Wullich B. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int. J. Cancer 2012, 130:611-621.
117. Ambs S., Prueitt R.L., Yi M., Hudson R.S., Howe T.M., Petrocca F., Wallace T.A., Liu C.G., Volinia S., Calin G.A., Yfantis H.G., Stephens R.M., Croce C.M. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68:6162-6170.
118. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67:6130-6135.
119. Tong A.W., Fulgham P., Jay C., Chen P., Khalil I., Liu S., Senzer N., Eklund A.C., Han J., Nemunaitis J. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009, 16:206-216.
120. Hagman Z., Larne O., Edsjo A., Bjartell A., Ehrnstrom R.A., Ulmert D., Lilja H., Ceder Y. MiR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int. J. Cancer 2010, 127:2768-2776.
121. Selth L.A., Townley S., Gillis J.L., Ochnik A.M., Murti K., Macfarlane R.J., Chi K.N., Marshall V.R., Tilley W.D., Butler L.M. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int. J. Cancer 2011.
122. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
123. Haffner M.C., Chaux A., Meeker A.K., Esopi D.M., Gerber J., Pellakuru L.G., Toubaji A., Argani P., Iacobuzio-Donahue C., Nelson W.G., Netto G.J., De Marzo A.M., Yegnasubramanian S. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2:627-637.
124. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
125. Irizarry R.A., Ladd-Acosta C., Wen B., Wu Z., Montano C., Onyango P., Cui H., Gabo K., Rongione M., Webster M., Ji H., Potash J.B., Sabunciyan S., Feinberg A.P. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 2009, 41:178-186.
126. Hansen K.D., Timp W., Bravo H.C., Sabunciyan S., Langmead B., McDonald O.G., Wen B., Wu H., Liu Y., Diep D., Briem E., Zhang K., Irizarry R.A., Feinberg A.P. Increased methylation variation in epigenetic domains across cancer types. Nat. Gene. 2011, 43:768-775.
127. Enokida H., Shiina H., Urakami S., Igawa M., Ogishima T., Pookot D., Li L.C., Tabatabai Z.L., Kawahara M., Nakagawa M., Kane C.J., Carroll P.R., Dahiya R. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int. J. Cancer 2005, 116:174-181.
128. Trock B.J., Brotzman M.J., Mangold L.A., Bigley J.W., Epstein J.I., McLeod D., Klein E.A., Jones J.S., Wang S., McAskill T., Mehrotra J., Raghavan B., Partin A.W. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 2011.
129. Hoque M.O., Topaloglu O., Begum S., Henrique R., Rosenbaum E., Van Criekinge W., Westra W.H., Sidransky D. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J. Clin. Oncol. 2005, 23:6569-6575.
130. Tokumaru Y., Harden S.V., Sun D.I., Yamashita K., Epstein J.I., Sidransky D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin. Cancer Res. 2004, 10:5518-5522.
131. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., Bova G.S., De Marzo A.M., Isaacs W.B., Nelson W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 64:1975-1986.
132. Prior C., Guillen-Grima F., Robles J.E., Rosell D., Fernandez-Montero J.M., Agirre X., Catena R., Calvo A. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J. Urol. 2010, 28:681-686.
133. Singal R., Ferdinand L., Reis I.M., Schlesselman J.J. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol. Rep. 2004, 12:631-637.
134. Maruyama R., Toyooka S., Toyooka K.O., Virmani A.K., Zochbauer-Muller S., Farinas A.J., Minna J.D., McConnell J., Frenkel E.P., Gazdar A.F. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 2002, 8:514-519.
135. Vener T., Derecho C., Baden J., Wang H., Rajpurohit Y., Skelton J., Mehrotra J., Varde S., Chowdary D., Stallings W., Leibovich B., Robin H., Pelzer A., Schafer G., Auprich M., Mannweiler S., Amersdorfer P., Mazumder A. Development of a multiplexed urine assay for prostate cancer diagnosis. Clin. Chem. 2008, 54:874-882.
136. Liu L., Kron K.J., Pethe V.V., Demetrashvili N., Nesbitt M.E., Trachtenberg J., Ozcelik H., Fleshner N.E., Briollais L., van der Kwast T.H., Bapat B. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int. J. Cancer 2011, 129:2454-2462.
137. Henrique R., Ribeiro F.R., Fonseca D., Hoque M.O., Carvalho A.L., Costa V.L., Pinto M., Oliveira J., Teixeira M.R., Sidransky D., Jeronimo C. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin. Cancer Res. 2007, 13:6122-6129.
138. Richiardi L., Fiano V., Vizzini L., De Marco L., Delsedime L., Akre O., Tos A.G., Merletti F. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J. Clin. Oncol. 2009, 27:3161-3168.
139. Liu L., Yoon J.H., Dammann R., Pfeifer G.P. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002, 21:6835-6840.
140. Nakayama T., Watanabe M., Yamanaka M., Hirokawa Y., Suzuki H., Ito H., Yatani R., Shiraishi T. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest. 2001, 81:1049-1057.
141. Kito H., Suzuki H., Ichikawa T., Sekita N., Kamiya N., Akakura K., Igarashi T., Nakayama T., Watanabe M., Harigaya K., Ito H. Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate 2001, 49:110-115.
142. Lou W., Krill D., Dhir R., Becich M.J., Dong J.T., Frierson H.F., Isaacs W.B., Isaacs J.T., Gao A.C. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 1999, 59:2329-2331.
143. Wolters T., Vissers K.J., Bangma C.H., Schroder F.H., van Leenders G.J. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int. 2010, 106:280-286.
144. Chalitchagorn K., Shuangshoti S., Hourpai N., Kongruttanachok N., Tangkijvanich P., Thong-ngam D., Voravud N., Sriuranpong V., Mutirangura A. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004, 23:8841-8846.
145. Delgado-Cruzata L., Hruby G.W., Gonzalez K., McKiernan J., Benson M.C., Santella R.M., Shen J. DNA methylation changes correlate with gleason score and tumor stage in prostate cancer. DNA Cell Biol. 2012, 31:187-192.
146. Florl A.R., Steinhoff C., Muller M., Seifert H.H., Hader C., Engers R., Ackermann R., Schulz W.A. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 2004, 91:985-994.
147. Gonzales J.C., Fink L.M., Goodman O.B., Symanowski J.T., Vogelzang N.J., Ward D.C. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 2011, 9:39-45.
148. Selth L.A., Townley S., Gillis J.L., Ochnik A.M., Murti K., Macfarlane R.J., Chi K.N., Marshall V.R., Tilley W.D., Butler L.M. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int. J. Cancer. J. Int. du Cancer 2011.
149. Hao Y., Zhao Y., Zhao X., He C., Pang X., Wu T.C., Califano J.A., Gu X. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest. 2011, 29:318-324.
150. Yaman Agaoglu F., Kovancilar M., Dizdar Y., Darendeliler E., Holdenrieder S., Dalay N., Gezer U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour. Biol. 2011, 32:583-588.
151. Bryant R.J., Pawlowski T., Catto J.W., Marsden G., Vessella R.L., Rhees B., Kuslich C., Visakorpi T., Hamdy F.C. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106:768-774.